Key result
Pegylated liposomal doxorubicin matches conventional doxorubicin response in metastatic breast and recurrent ovarian cancer.
Why the study?
Pegylated liposomal doxorubicin was developed to maintain or enhance doxorubicin's antineoplastic effects while improving its toxicity profile in breast and ovarian cancers.
Does pegylated liposomal doxorubicin improve objective responses and toxicity in patients with breast and ovarian cancers compared to doxorubicin and other single agents?
Does pegylated liposomal doxorubicin improve objective responses and toxicity in patients with breast and ovarian cancers compared to doxorubicin and other single agents?
Pegylated liposomal doxorubicin is an effective treatment with an improved toxicity profile for metastatic breast cancer and recurrent/platinum-resistant ovarian cancer.
Answers are grounded in this paper and cite their sources.
May support consideration in metastatic breast and recurrent ovarian cancers; leaves open optimal dosing and sequencing in confirmatory trials.
Peglyated liposomal doxorubicin was developed to maintain or enhance the demonstrated antineoplastic effects of doxorubicin, while improving the toxicity profile associated with this important cytotoxic agent. Accumulating clinical data have confirmed the activity of pegylated liposomal doxorubicin in cancers of the breast and ovary. Furthermore, Phase II and III trial experience has revealed that the drug produces objective responses comparable in rate and duration to doxorubicin and other single agents employed in metastatic breast cancer. In recurrent and platinum-resistant ovarian cancer, single-agent pegylated liposomal doxorubicin has assumed an important role in routine patient management.
No takes yet. Share an insight, caveat, or question.
Maurie Markman (2006) conducted a review in Cancers of the breast and ovary. Pegylated liposomal doxorubicin vs. Doxorubicin and other single agents was evaluated. Pegylated liposomal doxorubicin produces objective responses comparable to doxorubicin in metastatic breast cancer and plays an important role in recurrent and platinum-resistant ovarian cancer.
Synapse has enriched 10 related papers. Consider them for comparative context: